ETFS Holding Santarus, Inc.

 
News Articles for Santarus, Inc. top ^
Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter ended June 30, 2013.
Sign-up for Santarus Reports Second Quarter 2013 Financial Results investment picks
2013/9/3
Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.
Sign-up for Santarus to Present at September Investment Conferences investment picks
2013/10/4
Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX ® in patients with travelers’ diarrhea will be featured in a poster presentation at IDWeek ™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013.
Sign-up for Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea investment picks
2013/10/25
Santarus, Inc. (NASDAQ:SNTS) today announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin), will be featured in a poster presentation at the 2013 American College of Rheumatology.
Sign-up for Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting investment picks
Santarus, Inc. (NASDAQ:SNTS) today announced that it will release third quarter 2013 financial results after market close on Thursday, November 7, 2013.
Sign-up for Santarus to Hold Third Quarter 2013 Financial Results Conference Call on November 7 investment picks
NEW YORK , Nov.
Sign-up for Harwood Feffer LLP Announces Investigation of Santarus, Inc. investment picks
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ:SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd.
Sign-up for Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Santarus, Inc. Stockholders investment picks
2013/11/8
Law Offices of Howard G.
Sign-up for Law Offices of Howard G. Smith Announces Investigation of Santarus Inc. investment picks
2013/11/8
Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) is investigating the acquisition of Santarus, Inc. (NASDAQ: SNTS) by Salix Pharmaceuticals Ltd.
Sign-up for Wolf Haldenstein Announces Investigation of Acquisition of Santarus, Inc. investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Santarus, Inc. (“Santarus”) (NasdaqGS: SNTS) related to the acquisition by Salix Pharma for shareholders.
Sign-up for Santarus Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Salix Pharma investment picks
Holzer Holzer & Fistel, LLC is investigating whether the directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ: SNTS) complied with their fiduciary duties in connection with the proposed buyout of the Company by Salix Pharmaceuticals, Ltd.
Sign-up for Investor Alert: Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Santarus, Inc. investment picks
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Santarus, Inc. (Nasdaq: SNTS) (“Santarus” or “the Company”), concerning the Company’s proposed acquisition by Salix Pharmaceuticals Ltd.
Sign-up for Finkelstein Thompson LLP Announces Investigation of Santarus, Inc. Buyout Proposal investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether the Board of Directors of Santarus, Inc. (Nasdaq: SNTS) breached its fiduciary duties in connection with the Company’s proposed acquisition by Salix Pharmaceuticals, Ltd.
Sign-up for Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of the Santarus, Inc. Proposed Acquisition by Salix Pharmaceuticals, Ltd. investment picks
2013/11/8
Rigrodsky & Long, P.A.: Do you own shares of Santarus, Inc. (NASDAQ GS: SNTS )? Did you purchase any of your shares prior to November 7, 2013?
Sign-up for SANTARUS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2013/11/8
The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Santarus, Inc. (“Santarus”) (NASDAQ: SNTS) and other violations of state law by the board of directors of Santarus relating to the proposed buyout of the Company by Salix Pharmaceuticals, Ltd.
Sign-up for Law Firm Brower Piven Announces Investigation of Santarus, Inc. Proposed Buyout investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Santarus, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Sanofi  |  Next: ETFS Holding Sap AG